All In Biotech

NDA 020990 · Viatris

Zoloft

Sertraline Hydrochloride · Oral

Last checked: Nov 20, 2026Latest source record: Aug 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1999

Dec 7, 1999

Approved uses

9

Original approval plus efficacy supplements

Registered trials

369

75 Phase 3, 32 recruiting

FAERS reports

106,461

67,510 serious, 7,543 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [See Warnings and Precautions (5.1) ] . WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. • Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients ( 5.1 ) • Closely monitor for clinical worsening and emergence of suicidal thoughts and behaviors ( 5.1 )

What it is approved for

From the label in effect Sep 15, 2024.

Sertraline hydrochloride oral solution is indicated for the treatment of the following [See Clinical Studies (14) ] : • Major depressive disorder (MDD) • Obsessive-compulsive disorder (OCD) • Panic disorder (PD) • Posttraumatic stress disorder (PTSD) • Social anxiety disorder (SAD) • Premenstrual dysphoric disorder (PMDD) Sertraline hydrochloride oral solution is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of ( 1 ): • Major depressive disorder (MDD) • Obsessive-compulsive disorder (OCD) • Panic disorder (PD) • Posttraumatic stress disorder (PTSD) • Social anxiety disorder (SAD) • Premenstrual dysphoric disorder (PMDD)

Mechanism: Sertraline potentiates serotonergic activity in the central nervous system through inhibition of neuronal reuptake of serotonin (5-HT).

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ZOLOFT · SERTRALINE HYDROCHLORIDE EQ 20MG BASE/ML · CONCENTRATE, ORAL · Prescription · TE AA

Clinical trials

Interventional ClinicalTrials.gov studies with "Sertraline" as an intervention, any sponsor and status, largest first.

All 369 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea7,583
  • fatigue7,146
  • drug ineffective6,961
  • headache6,380
  • anxiety5,948
  • depression5,895
  • pain5,248
  • diarrhoea5,226
  • dizziness5,121
  • dyspnoea4,629
  • insomnia4,136
  • vomiting4,129

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043,246
20053,227
20062,879
20072,463
20082,089
20092,791
20105,405
20116,158
20127,062
20134,978
20144,537
20156,116
20166,178
20175,666
20185,359
20195,166
20204,843
20214,310
20225,429
20234,539
20244,772
20255,160
20264,083

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zoloft (Sertraline HCl)

2024 spending

$14.1M

Beneficiaries

2,841

13,450 claims

Per beneficiary

$4,977

$13.81 per unit

View as table
YearSpending
2020$18,100,083
2021$15,325,746
2022$14,396,286
2023$13,954,039
2024$14,138,763

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,445 on PubMed

Sponsor: Viatris

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.